Evidence map›Paper›PMID 35923274›Full record

ReviewBulletin of the World Health Organization2022

Reclassifying contraceptives as over-the-counter medicines to improve access.

Anne Ammerdorffer, Mark Laws, Manjulaa Narasimhan, Briana Lucido, Agnes Kijo, Lale Say, Arinze Awiligwe, Lester Chinery, A Metin Gülmezoglu

Open access · diamondAbstract readReview
In one paragraph

Review in Bulletin of the World Health Organization, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Anne AmmerdorfferConcept Foundation, Bâtiment F2F3, Avenue de Sécheron 15, Geneva, 1202, Switzerland.
Mark LawsConcept Foundation, Bâtiment F2F3, Avenue de Sécheron 15, Geneva, 1202, Switzerland.
Manjulaa NarasimhanDepartment of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
Briana LucidoDepartment of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
Agnes KijoRegulatory Convergence and Networks Team, World Health Organization, Geneva, Switzerland.
Lale SayDepartment of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
Arinze AwiligweConcept Foundation, Bâtiment F2F3, Avenue de Sécheron 15, Geneva, 1202, Switzerland.
Lester ChineryConcept Foundation, Bâtiment F2F3, Avenue de Sécheron 15, Geneva, 1202, Switzerland.
A Metin GülmezogluConcept Foundation, Bâtiment F2F3, Avenue de Sécheron 15, Geneva, 1202, Switzerland.
World Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

Self-care interventions include over-the-counter contraceptives, which enable individuals to make informed, autonomous decisions about fertility management. As there is a substantial unmet need for contraception in many countries, increasing access by establishing sound, affordable and effective regulation of over-the-counter contraceptives could help reduce unintended pregnancies and improve maternal health. We performed a review of 30 globally diverse countries: (i) to assess national regulatory procedures for changing oral contraceptives, emergency contraceptives and injectable contraceptives from prescription-only to over-the-counter products; and (ii) to determine whether national lists of over-the-counter medicines included contraceptives. Of the 30 countries, 13 (43%) had formal regulatory procedures in place for changing prescription-only medicines to over-the-counter medicines, 11 (36%) had national lists of over-the-counter medicines, and four (13%) included contraceptives on those lists. Changing from prescription-only to over-the-counter medicines presents challenges for national medicines regulatory authorities and manufacturers, involving, for example, reporting side-effects, quality control and the often poorly-defined process of switching to over-the-counter products. To facilitate the over-the-counter availability of contraceptives, countries should consider adopting a formal regulatory procedure for reclassifying prescription-only contraceptives as over-the-counter contraceptives. Although the availability of over-the-counter contraceptives can increase users' independence and anonymity and improve access, there may also be disadvantages, such as higher out-of-pocket costs and the need for accurate self-assessment. Basic remedial actions to improve, harmonize and standardize regulatory procedures for the reclassification of contraceptives are proposed with the aim of enabling national medicines regulatory authorities to manage the switch to over-the-counter contraceptives and to control their quality.

Indexed as

Contraceptives, OralNonprescription DrugsContraceptionFemaleHealth ExpendituresHumansPregnancyPregnancy, UnplannedContraceptives, OralNonprescription Drugs

Identifiers

PMID35923274
PMCPMC9306387
OpenAlexW4289527961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.